Successful treatment with CPT-11 plus S-1 therapy in a patient with primary signet- ring cell carcinoma of the uterine cervix: A case report and literature review

We report our experience with a case in which primary signet-ring cell carcinoma of the uterine cervix was successfully treated with CPT-11 plus S-1 therapy. The patient was a 45-year-old woman with stage IIIB primary signet-ring cell carcinoma of the uterine cervix. The uterine cervix had enlarged to 8 cm; the right ovarian tumor was 15 cm in size; and there was an 8-cm cystic mass in the left ovary. After five cycles of CPT-11 plus S-1 therapy, the tumor shrinkage rate was 52.2% and the tumor response was partial response. To improve symptoms, left adnexectomy was performed, and CPT-11 plus S-1 therapy was continued. To date, 11 cycles have been performed without dose reduction or delay of therapy. No adverse event of grade 3 or higher has been observed. CPT-11 plus S-1 therapy was effectively and safely performed to treat signet-ring cell carcinoma of the uterine cervix that is difficult to treat. This is the first case in which primary signet-ring cell carcinoma of the uterus responded well to CPT-11 plus S-1 therapy.

Cervical cancer; Signet-ring cell carcinoma; CPT-11; S-1.

[1] Haswani P., Arseneau J., Ferenczy A.: “Primary signet ring cell carcinoma of the uterine cervix: A clinicopathologic study of two cases with review of the literature”. Int. J. Gynecol. Cancer, 1998, 8, 374–379.

[2] Yoon A., Kim S., Kim H., Bae D., Lee J.: “Primary signet ring cell carcinoma of the uterine cervix: A case report”. Korean J. Obstet. Gynecol., 2011, 54, 570.

[3] Sal V., Kahramanoglu I., Turan H., Tokgozoglu N., Bese T., Aydin O., et al.: “Primary signet ring cell carcinoma of the cervix: A case report and review of the literature”. Int. J. Surg. Case Rep., 2016, 21, 1-5.

[4] Young R.H., Clement P.B.: “Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis”. Histopathology, 2002, 41, 185-207.

[5] Moll U.M., Chumas J.C., Mann W.J., Patsner B.: “Primary signet ring cell carcinoma of the uterine cervix”. N. Y. State J. Med., 1990, 90, 559-560.

[6] Cardosi R.J., Reedy M.B., van Nagell J.R., Spires S.E.: “Neuroendocrine signet ring cell adenocarcinoma of the endocervix”. Int. J. Gynecol. Cancer, 1999, 9, 433-437.

[7] Moritani S., Ichihara S., Kushima R., Sugiura F., Mushika M., Silverberg S.G.: “Combined signet ring cell and glassy cell carcinoma of the uterine cervix arising in a young Japanese woman: A case report with immunohistochemical and histochemical analyses”. Pathol. Int., 2004, 54, 787-792.

[8] Insabato L., Simonetti S., De Cecio R., Di Tuoro S., Bifulco G., Di Spiezio Sardo A.: “Primary signetring cell carcinoma of the uterine cervix with long term follow-up: case report”. Eur. J. Gynaecol. Oncol., 2007, 28, 411-414.

[9] Lowery W.J., Difurio M.J., Sundborg M.J., Leath C.A.: “Cervical signetring cell carcinoma presenting as a synchronous primary carcinoma with uterine adenocarcinoma”. Mil. Med., 2009, 174, 212-213.

[10] Veras E., Srodon M., Neijstrom E.S., Ronnett B.M.: “Metastatic HPV-related cervical adenocarcinomas presenting with thromboembolic events (Trousseau Syndrome): Clinicopathologic characteristics of 2 cases”. Int. J. Gynecol. Pathol., 2009, 28, 134-139.

[11] Giordano G., Pizzi S., Berretta R., D’Adda T.: “A new case of primary signetring cell carcinoma of the cervix with prominent endometrial and myometrial involvement: Immunohistochemical and molecular studies and review of the literature”. World J. Surg. Oncol., 2012, 10, 7.

[12] Kaidar-Person O., Amit A., Berniger A., Ben-Yosef R., Kuten A., Bortnyak-Abdah R.: “Primary signetring cell adenocarcinoma of the uterine cervix: case report and review of the literature”. Eur. J. Gynaecol. Oncol., 2013, 34, 353-354.

[13] Cracchiolo B., Kuhn T., Heller D.: “Primary signet ring cell adenocarcinoma of the uterine cervix — A rare neoplasm that raises the question of metastasis to the cervix”. Gynecol. Oncol. Rep., 2016, 16, 9-10.

[14] Wang Y.C., Yu Y.L., Fan C.W., Huang S.Y.: “Primary signet ring cell carcinoma of the cervix: A case report with review of the literature”. Taiwan J. Obstet. Gynecol., 2019, 58, 308.

[15] Narahara H., Iishi H., Imamura H., Tsuburaya A., Chin K., Imamoto H., et al.: “Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)”. Gastric. Cancer, 2011, 14, 72-80.